CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Lavender (Lavandula angustifolia)drug
Likely dose
Not stated in record
Key inclusion· 1
  • Age 18 years or older
Key exclusion· 5
  • Allergy or sensitivity to lavender
  • Aversion to lavender scent
  • History of asthma or COPD
  • History of contact dermatitis from cosmetic fragrances

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03328143
NCT03328143Phase 1Completed

Feasibility of Aromatherapy in an Awake Craniotomy Environment

Wake Forest University Health Sciences·interventional·Posted Nov 1, 2017·Updated Oct 3, 2024

In Brief

A Phase 1 clinical trial evaluating Lavender (Lavandula angustifolia) for Intracranial Pathology. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Awake craniotomy for tumor surgery allows for mapping of speech, motor and sensory function during tumor resection. Awake craniotomy is increasingly utilized as it has several advantages over a traditional general anesthetic technique. Though many patients tolerate awake cranial surgery well, recent studies found that roughly 30% of patients experience moderate to severe pain and anxiety, while 50% report moderate fear and 11% report severe fear. Therefore, alternative methods to mitigate pain, anxiety, and fear are needed. In this study, the investigators will employ lavender aromatherapy to reduce anxiety and improve the satisfaction with pain control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedNov 1, 2017
Enrollment StartApr 3, 2018
Primary CompletionJun 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.7 years ago

Interventions

Lavender (Lavandula angustifolia)drug

Lavender (Lavandula angustifolia) is an essential oil.